Views Article – Sharenet Wealth

Europe, News

Bharat Biotech’s COVID-19 shot safe, produced immune response in early human trial – The Lancet

By Manojna Maddipatla

Jan 22 (Reuters) – Indian drugmaker Bharat Biotech’s coronavirus vaccine, which has been authorized for use in the country, proved safe and produced an immune response in a small group of adults aged 18 to 55, according to a study published in The Lancet medical journal.

The vaccine, developed with the Indian Council of Medical Research (ICMR), is being evaluated in a separate 25,800 person trial, which started in November. Bharat Biotech said on Friday 13,000 people participating in the late-stage trial had been given the second dose.

The interim data published https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30942-7/fulltext in the journal included three different vaccine formulations and a placebo group among 375 adults.

Two formulations of the vaccine, called COVAXIN, have been selected for more advanced stages of testing and further efficacy trials are warranted, the report said.

COVAXIN is an inactivated vaccine that introduces dead virus into the body to trigger an immune response.

This is the first peer reviewed data for the vaccine that has come under scrutiny after widespread criticism over the lack of transparency on the approval process for the shot.

The vaccine was granted emergency approval by the drugs controller general of India this month along with another vaccine, Covishield, developed by AstraZeneca and Oxford University.

India, which has reported the highest number of coronavirus infections after the United States, kicked off its own vaccination drive on Saturday in what the government called the “world’s largest vaccination program.”

(Reporting by Manojna Maddipatla in Bengaluru, additional reporting by Ankur Banerjee and Julie Steenhuysen; Editing by Caroline Humer in New York and Sriraj Kalluvila)


© 2019 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. "Reuters" and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.